Impact of sleep-related hypoventilation in patients with pleuroparenchymal fibroelastosis

Yuki Yabuuchi1,5*, Takefumi Saito1, Hitomi Hirano1, Mizu Nonaka1, Naoki Arai1, Kentaro Hyodo1, Jun Kanazawa1, Yukiko Miura1, Shingo Usui2, Katsumi Tamura3, Tomotaka Kasamatsu4, Shuji Ohishi1, Kenji Hayashihara1, Masashi Matsuyama5 and Nobuyuki Hizawa5

Abstract

Background: Pleuroparenchymal fibroelastosis (PPFE) is a rare fibrosing lung disease with a predilection for the upper lobe and its progression causes hypoventilation, resulting in hypercapnia. Even though the association between sleep-related hypoventilation (SRH) and chronic obstructive pulmonary disease was well documented, its impact in patients with PPFE was not evaluated. The aim of this study is to clarify the impact of SRH on prognosis in PPFE.

Methods: A retrospective review of the medical records of 52 patients with PPFE who underwent transcutaneous carbon dioxide monitoring during sleep was done. Patients were stratified into SRH (n = 28) and non-SRH (n = 24) groups based on American Academy of Sleep Medicine criteria. The impact of SRH on the prognosis of PPFE, as well as the clinical factors and comorbidities of PPFE associated with SRH, were evaluated.

Results: Forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), and carbon monoxide diffusing capacity (DLco) in the SRH group were significantly lower than the non-SRH group (P < .01). Chronic pulmonary aspergillosis (CPA) was found at a higher rate in the SRH group (P = .02). The median survival time for SRH patients was 330 days, whereas roughly 80% of non-SRH patients were alive during the 3-year observation period (P < .01). Body mass index was a significant prognostic factor in PPFE patients with SRH (HR .78; 95% CI; .64–.94; P < .01). Home oxygen therapy (HOT) during the day and noninvasive positive pressure ventilation (NPPV) at night while sleeping tended to improve prognosis in the SRH group, as indicated by HR of .25 (P = .07).

Conclusions: SRH may be a poor prognostic factor for PPFE. Additionally, SRH may modify susceptibility to Aspergillosis in patients with PPFE. HOT plus NPPV may improve the disease outcomes in patients with SRH.

Keywords: Partial pressure of carbon dioxide, Transcutaneous carbon dioxide, Non-invasive positive pressure ventilation, Chronic pulmonary aspergillosis
failure from an early stage, in the form of increase in the partial pressure of carbon dioxide (PaCO₂), which is distinctly different from other IIPs [2, 3]. The mechanism of these changes has not been elucidated, but may be related to fibrotic changes in the bilateral upper lobes and limited mobility of the chest wall [2].

Sleep-related hypoventilation (SRH) was one of the sleep-related respiratory disorders described in the International Classification of Sleep Disorder (ICSD) 3rd edition as the impairment of ventilation during sleep, resulting in the elevation of the PaCO₂ [4, 5]. The American Academy of Sleep Medicine (AASM) suggested the following criteria for SRH: PaCO₂ during sleep increases >55 mmHg for ≥10 min or PaCO₂ during sleep increases >10 mmHg compared with awake supine values exceeding 50 mmHg for ≥10 min [4]. SRH is subdivided into subtypes and SRH due to a medical disorder [5] is subsequently induced from chronic respiratory diseases presenting with thoracic deformity and respiratory disease consisting of the lung parenchyma, airways, or pulmonary vascular disorders [5, 6], which likely occur in PPFE. Some studies have investigated the association between SRH and chronic obstructive pulmonary disease (COPD) [6–8]. However, as far as we know, studies evaluating the impact of SRH on PPFE are scarce in the published literature. In the current study, we evaluated the effect of secondary SRH on survival outcomes in patients with PPFE.

Methods
Study population
We retrospectively reviewed the medical records of 52 consecutive patients diagnosed with PPFE at a tertiary care center who were assessed with transtcutaneous carbon dioxide monitoring (PtCO₂) during sleep over a span of three years. The study protocol was approved by the Institutional Ethics Committee (No. 2019-027). All procedures in this study were performed according to the ethical standards of the Institutional Research Committee and adhered to the tenets of the Helsinki Declaration (1964). The opt-out method was used for patient consent instead of obtaining informed consent.

Measurement
Parameters such as age, sex, body mass index (BMI), smoking history, serum levels of Krebs von den lungen-6 (KL-6), arterial blood gas analysis (ABG), and respiratory comorbidities were evaluated. The pulmonary function test (PFT) (CHESTAC-8900; Chest, Tokyo, Japan) and diffusing capacity for carbon monoxide (DLₐCO) using the single-breath method (CHESTAC-8900) were also measured. The PFT was conducted according to the American Thoracic Society (ATS) recommendations for acceptability and reproducibility [9]. Using spirometry, forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), FEV₁/FVC, VC, total lung capacity (TLC), residual volume (RV), DLₐCO, and DLₐCO/ alveolar volume (Vₐ) were evaluated. The values of FEV₁, FVC, VC, TLC, RV, RV/TLC, DLₐCO, and DLₐCO/Vₐ were expressed as percentages of the predicted values. Additionally, the gender-age-physiology (GAP) score was evaluated, as the prognostic value for idiopathic pulmonary fibrosis (IPF) [10].

ABG samples were collected when a patient was awake, in a resting state, and in the supine position. The levels of PaCO₂ and hydrogen carbonate (HCO₃⁻) were evaluated within the normal pH range of 7.35 to 7.45. To analyze nocturnal PtCO₂ during sleep, a transtcutaneous blood gas monitoring system (TOSCA®) was used. The sensor worn on the earlobe had a built-in heating system that raised the skin temperature to 42 °C to increase both blood flow and CO₂ diffusion and detects CO₂ value [11]. Generally, skin CO₂ is higher than blood PaCO₂; therefore, PtCO₂ was carbureted, thereby calculating approximate PaCO₂ [11]. Modern PtCO₂ monitoring systems are extremely precise and have an accuracy level within that of PtCO₂ and PaCO₂ [8, 11, 12]. PaO₂ and the mean and maximum values of PtCO₂ during sleep were evaluated.

To analyze the association between SRH and platythorax, a flat chest index was estimated [13]. For each patient, clinical events and survival were followed for 3 years after the presence of SRH was evaluated. Clinical events included the occurrence of respiratory adverse events, cause of death, introduction of drug therapies (nintedanib, pirfenidone, prednisolone, and immunosuppressant), non-invasive positive pressure ventilation (NPPV) during sleep, and home oxygen therapy (HOT) during the day. A medical team consisting of pulmonologists (YY, TS) and radiologists (TK, KT) with over 20 years of experience evaluated the high-resolution computed tomography (HRCT) scans. The clinical course of the patient was reviewed by the attending physician, a respiratory specialist. Since no significant differences in the clinical course or outcome have been reported between idiopathic and secondary PPFE [14], this study does not include a detailed examination of the etiology of individual cases.

GAP score
The GAP score was classified 0–3 for Stage I, 4 and 5 for Stage II, and 6–8 for Stage III, and as the stage progressed, the prognosis became worse in IPF [10]. Based on recent literature, the GAP score can also be applied in PPFE [15, 16]; therefore, wherever the data were available, participants were stratified as Stage I – III.
Flat chest index
It has been reported that the thoracic cage becomes flat with the progression of PPFE, resulting from fibrotic collapse in the upper lobes [13, 17]. These changes may induce compensatory overinflation in the lower lobes, which reflects an increase in the RV/TLC [2, 17]. The flat chest index presented the degree of platythorax, defined as the ratio of the anteroposterior diameter to the transverse diameter in the thoracic cage at the level of the sixth thoracic vertebra on chest CT [13]. In this study, this parameter was measured in the participants who underwent chest CT.

Diagnosis of PPFE
PPFE was mainly diagnosed by HRCT based on Reddy’s criteria [18] and clinical findings, as mentioned in previous studies [14, 15, 19, 20]. Pathological findings, wherever available were used as references; however, lung biopsy may carry a high risk of secondary pneumothorax and surgical lung biopsy is not recommended [19, 20]. Enomoto et al. [20] defined the clinical diagnostic criteria of idiopathic PPFE as follows: (1) Radiological findings of definite PPFE (bilateral subpleural dense consolidation with or without pleural thickening and/or a reduction of volume in the upper lobes). (2) Radiological disease progression (an increase in upper lobe consolidation with or without pleural thickening and/or reduction of volume in the upper lobes). (3) Exclusion of differential lung diseases (such as connective tissue disease-related interstitial lung disease, chronic hypersensitivity pneumonitis, pulmonary sarcoidosis, pneumoconiosis, and active pulmonary infection). We did not distinguish between idiopathic and secondary PPFE in this study; therefore, the third criterion was not used.

Comorbidities assessed in the study included COPD, bronchial asthma (BA), radiological lower-lobe interstitial lung disease (ILD) in usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), and chronic pulmonary aspergillosis (CPA). The diagnosis of COPD, BA, and CPA was based on established criteria [21–23]. UIP and NSIP on HRCT were also based on the established criteria [24].

Diagnosis of SRH
SRH was diagnosed using AASM criteria [4]. Some reports have shown a strong correlation between PtCO2 and PaCO2 [11, 12]; therefore, levels of PaCO2 during sleep were substituted by PtCO2, while awakening PaCO2 was measured by arterial blood gas (ABG) in a resting state and in the supine position. In this regard, the SRH criteria in the AASM were modified to PtCO2 increasing > 10 mmHg compared with awake supine values in PaCO2 of ABG exceeding 50 mmHg for ≥ 10 min. PtCO2 was performed for PPFE patients who had been suspected of having ventilation disturbance based on symptoms, results of ABG, pulmonary function tests (PFT), chest X-ray (CXR), and HRCT.

To assess the condition of each patient over the course of the disease, we excluded patients with acute respiratory failure as follows: (1) patients were in the intensive care unit (ICU), (2) acute changes in the condition of the patient in the time period from examining PtCO2 to ABG, (3) acute respiratory diseases that were complicated during or just before PtCO2, (4) tranquilizers were used before PtCO2, and (5) patients who were managed with mechanical ventilation by intubation, non-invasive positive pressure ventilation (NPPV), continuous positive airway pressure, or nasal high flow oxygen therapy.

Data analysis
All data were presented as medians (interquartile ranges) for continuous variables and as numbers or percentages for categorical variables. The comparison between two categorical variables was evaluated using the chi-squared or Fisher’s exact test. The Mann–Whitney U-test was used to compare continuous variables. For analyzing overall survival for 3 years after TOSCA® evaluation, the Kaplan–Meier method was used to present the estimated survival probabilities and the comparison of survival rates was made by log-rank test. Additionally, univariate and multivariate Cox proportional hazards models were applied to analyze independent predictors of survival. Stepwise regression was used to select explanatory variables in the multivariate analysis. The predictive factors were age, smoking history, BMI, male gender, PaCO2, HCO3−, PtCO2 mean, PtCO2 max, %FEV1, FEV1/FVC, %VC, %FVC, %TLC, %RV, %RV/TLC, %DLCO, %DLCO/V.A, KL-6, GAP score stage, flat chest index, and HOT + NPPV.

In this study, all variables with P < .05 were defined as statistically significant. Data analysis was performed using R software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria).

Results
Among 52 consecutive patients with PPFE, 28 (53.8%) were diagnosed as having SRH. The clinical characteristics of the study participants are listed in Table 1. The mean age, sex, smoking history, body mass index, and KL-6 of the enrolled patients had no differences between the SRH and non-SRH groups. As a matter of course, both mean and max PtCO2 in the SRH group were higher than in the non-SRH group with a significant statistical difference. Differences were also
observed in the results of pulmonary function tests and DLCO using the single-breath method. The SRH group progressed with pulmonary restrictive changes, namely decreased VC, and FVC, compared with the non-SRH group. The FRC, TLC, and RV in the SRH group were lower than those in the non-SRH group, indicating that the lung volume in the SRH group tended to shrink significantly compared to the non-SRH group. Moreover, the pulmonary diffusion capacity, DLCO, and DLCO/VA, of the SRH group were also worse than that of the non-SRH group, which likely highlighted the destruction of the alveolar wall and pulmonary capillary bed due to disease progression. Additionally, the results of ABG also reflected the difference between the SRH and the non-SRH group; levels of PaCO2 and HCO3− within the normal range of pH in the SRH group were obviously higher than those of the non-SRH group, which reflected chronic alveolar hypoventilation.

A comparison of baseline comorbidities between the SRH and non-SRH groups in PPFE patients is shown in Table 2. A higher frequency of CPA was found in the SRH group.

In patients with SRH in PPFE (n = 28), there were some events including death during the follow-up period (Table 3). Pneumothorax was the most common complication (n = 7), followed by bacterial pneumonia (n = 4) and CPA (n = 3). Sixteen patients died (57.1%), and the cause of death was the worsening of type-2 respiratory failure (68.7%). The causes of death in the remaining patients included pneumothorax (n = 3), acute exacerbation (n = 1), and sepsis (n = 1). Kaplan–Meier survival curves in the SRH and the non-SRH groups are presented in Fig. 1, which showed a significant difference (P < .01).

During the three years follow-up period, there were 16 deaths in 23 patients with SRH and 4 deaths in 22 traceable patients with non-SRH. Seven patients were
untraceable because of transfer to another hospital or self-interruption of medical check-ups. The median survival time in the SRH group was 330 days while about 80% patients are alive in the follow-up period in the non-SRH group (log-rank \( P < .01 \)).

The Cox proportional hazard ratio demonstrated a hazard ratio (HR) of 5.36; 95% confidence interval (CI); 1.94–14.82; \( P < .01 \), which identified SRH as a prognostic factor in PPFE.

Univariate Cox proportional hazards models were used to identify the prognostic factors in patients with SRH in PPFE, as listed in Table 4. The analysis demonstrated that BMI (HR .77; 95% CI; .64-.94; \( P < .01 \)) was a significant prognostic factor in patients with SRH in PPFE. In addition, 9 patients were managed with home oxygen therapy (HOT) during the daytime and NPPV during sleep. Five of the 9 patients (55.5%) died within the follow-up period (Table 3), whereas 11 patients (57.9%) died among the 14 who did not receive this therapy (\( P = .07 \)).

Furthermore, univariate and multivariate Cox proportional hazards models were used to construct prognostic models for all patients with PPFE, as shown in Table 5. In univariate analysis, the following factors demonstrated significant differences as prognostic factors, respectively; BMI (HR .74; 95% CI; .65–.85; \( P < .01 \)), \( \text{PaCO}_2 \) (HR 1.05; 95% CI; 1.02–1.09; \( P < .01 \)), \( \text{HCO}_3^- \) (HR 1.23; 95% CI; .65–.85; \( P < .01 \)), \( \text{PtCO}_2 \text{mean} \) (HR 1.04; 95% CI; 1.01–1.07; \( P = .02 \)), \( \text{PtCO}_2 \text{max} \) (HR 1.03; 95% CI; 1.01–1.06; \( P = .01 \)), %VC (HR .96; 95% CI; .94–.99; \( P = .01 \)), %FVC (HR .96; 95% CI; .94–.99; \( P < .01 \)), %DLCO (HR .98; 95% CI; .96–.99; \( P = .04 \)), GAP score stage (HR 2.44; 95% CI; 1.09–5.46; \( P = .03 \)), BMI (HR .68; 95% CI; .56–.83; \( P < .01 \)), and SRH (HR 4.84; 95% CI; 1.31–17.93; \( P = .02 \)).

The results indicated that SRH with BMI and GAP score stage may be useful factors as prognostic models in PPFE.

Discussion
This study aimed to determine whether the complication of SRH in patients with PPFE has an impact on their survival. To the best of our knowledge, there is no research on the relationship between PPFE and SRH. In this study, the SRH group had poor prognosis than the non-SRH group. Worsening of hypercapnic chronic respiratory failure was common reason of death in PPFE [20, 25].

| Table 2 | Comorbidities of SRH (n = 28) and non SRH (n = 24) in PPFE |
|---------------------------------|-----------------------------------------------------|
| Total (n = 52) | SRH (n = 28) | non SRH (n = 24) | p-value |
| COPD | 7 | 4 | 3 | 1 |
| BA | 3 | 2 | 1 | 1 |
| Lower lobe ILD (UIP/NSIP) | 4/7 | 3/2 | 1/5 | .22 |
| CPA | 6 | 6 | 0 | .02 |
| Pneumothorax | 10 | 6 | 4 | .73 |
| Bacterial pneumonia | 9 | 4 | 5 | .72 |

The data are presented as n

SRH sleep-related hypoventilation, PPFE pleuroparenchymal fibroelastosis, COPD chronic obstructive pulmonary disease, BA bronchial asthma, ILD interstitial lung disease, NSIP nonspecific interstitial pneumonia, CPA chronic pulmonary aspergillosis

Lower lobe ILD demonstrated UIP or NSIP pattern in HRCT

| Table 3 | Events after diagnosis of SRH in PPFE |
|-----------------|----------------------------------|
| Events | n |
| Respiratory complications | |
| Pneumothorax | 7 (25.0%) |
| Bacterial pneumonia | 4 (14.3%) |
| CPA | 3 (10.7%) |
| Acute exacerbation | 1 (3.5%) |
| Death at the end of follow up | 16 (57.1%) |
| Reasons of death | |
| Worsening of hypercapnia | 11 (68.7%) |
| Pneumothorax | 3 (18.7%) |
| Acute exacerbation | 1 (6.2%) |
| Sepsis | 1 (6.2%) |
| Introducing drug therapy | |
| Nintedanib | 3 (10.7%) |
| Alive after introducing | 0 (0%) |
| Death after introducing | 3 (100%) |
| Pirfenidone | 2 (7.1%) |
| Alive after introducing | 1 (50%) |
| Death after introducing | 1 (50%) |
| Prednisolone | 0 (0%) |
| Immunosuppressant (tacrolimus) | 1 (3.5%) |
| Alive after introducing | 1 (100%) |
| Death after introducing | 0 (0%) |
| Introducing home ventilator | |
| HOT + NPPV | 9 (32.1%) |
| Alive after introducing | 3 (33.3%) |
| Death after introducing | 5 (55.5%) |
| Untraceable because of transferring another hospital | 1 (11.1%) |

The data are presented as n (%)

SRH sleep-related hypoventilation, PPFE pleuroparenchymal fibroelastosis, CPA chronic pulmonary aspergillosis, HOT + NPPV introducing home oxygen therapy (HOT) during daytime plus non-invasive positive pressure ventilation (NPPV) during sleep
In addition, a subgroup of advancing disease types, the so-called progressive PPFE phenotype, has been recognized [2, 26]. The feature of progressive PPFE disease is characterized by the presence of co-existing usual interstitial pneumonia and complications of pneumothorax or pneumomediastinum, and the median survival described in this phenotype is less than 5 years [2]. In this study, we identified CPA as the comorbidity, presenting a significant difference between the SRH and non-SRH groups (Table 2). Although several studies have reported that fibrotic lesions of PPFE have susceptibility to Aspergillus infection [26, 27], the causal relationship between SRH and Aspergillus infection requires further investigation.

In general, the progression of the fibrotic process in PPFE tends to worsen hypercapnic respiratory failure, which is a characteristic clinical course compared to other ILDs [3, 25]. The mechanisms of hypoventilation in PPFE have not been established; however, the following characteristic conditions in PPFE may be associated: upper lobe predominantly fibrotic changes of the visceral pleura and subpleural parenchyma and platythorax with slender [1, 2, 13]. PFT in intra- and extra-thoracic deformities demonstrates characteristic changes with worsening of FVC and a mild decrease in TLC and an increase in the ratio of RV/TLC [1, 2, 14, 15]. The diffusion capacity of DL\textsubscript{CO} also decreases while preserving DL\textsubscript{CO}/VA [1, 2, 25, 26]. In this study, as shown in Table 1, PFT and diffusing capacity demonstrated that FVC, TLC, and DL\textsubscript{CO} in the SRH group were significantly lower than those in the non-SRH group. These changes strongly affected the GAP score stage, with the SRH group demonstrating an advanced stage with significant differences. In contrast, the ratio of RV/TLC was high and DL\textsubscript{CO}/VA was low in both groups, without significant differences. There was no difference between the SRH and the non-SRH groups in the flat chest index presenting with platythorax, which may have no association with hypercapnia. These results indicate that the presence of SRH reflects more restrictive and shrinking lung states in PPFE. During sleep, these changes may occur even in the early stages of PPFE [1, 5, 25]. Generally, in rapid eye movement (REM) sleep, a state of mild hypoventilation and upper airway stenosis is caused by atonia of the respiratory musculature, but not the diaphragm [5, 6]. In PPFE, the progression of fibrosis and pleurodesis in the upper lobe may restrict the disturbance of diaphragmatic movements [1, 25, 27]. These conditions may impair ventilation, resulting in the development of hypercapnia during REM sleep.

It has been reported that NPPV may improve diurnal and nocturnal PaCO\textsubscript{2} and probably survival, especially in COPD [5–7]. While NPPV can be adapted to PPFE remains controversial, in this study, NPPV was introduced in nine cases, and three patients were alive.
during the follow-up period. In univariate Cox hazard proportional models, although no significant difference was proven, HOT in daytime plus NPPV in sleep may improve the prognosis of PPFE patients with SRH, as presented in HR of .25. Given that NPPV plus oxygen supplementation during sleep for hypercapnia in COPD improved quality of life and daytime PaCO2 compared with oxygen supplementation alone [28], this approach may also aid in PPFE. The optimal setting of NPPV for PPFE patients with SRH remains uncertain, however. Furthermore, the risk of pneumothorax in NPPV has been reported [29, 30]; therefore, deliberate discussions will be required before NPPV is introduced.

Limitations

The present study had several limitations. First, this study was performed at a single center with a relatively small sample size and had a retrospective study design. Future multicenter prospective studies with adequate sample sizes will be required to validate the data obtained. Second, there may be a small gap between PaCO2 and PtCO2 measured using the TOSCA® during sleep. In a single-center, 46-comparison study, Kelly et al. found that the average difference between PaCO2 and PtCO2 was 6.1 mmHg [31]. PtCO2 has been shown to have a slight positive bias compared to PaCO2 [7]. In the future, monitoring systems for PtCO2 during sleep need to be further improved in terms of accuracy. Third, it has not been revealed whether CPA associated with

Table 4 Univariate analysis of prognostic factors of SRH in PPFE

| Factor                  | HR [95% CI] | p-value |
|-------------------------|-------------|---------|
| Age                     | 1.02 [0.98–1.06] | .37     |
| Smoking history         | 2.19 [1.81–5.92] | .12     |
| BMI                     | 0.77 [0.64–0.94] | <.01    |
| Gender (male)           | 1.27 [0.43–3.74] | .66     |
| PaCO2                   | 1.01 [0.96–1.05] | .76     |
| HCO3⁻                   | 1.08 [0.95–1.24] | .25     |
| PtCO2, mean             | 0.98 [0.94–1.03] | .45     |
| PtCO2, max              | 0.99 [0.96–1.03] | .69     |
| %FEV1                   | 0.96 [0.25–3.68] | .95     |
| FEV1/FVC                | 1.01 [0.96–1.07] | .66     |
| %VC                     | 1.00 [0.97–1.04] | .83     |
| %FVC                    | 0.99 [0.96–1.03] | .73     |
| %TLC                    | 1.02 [0.98–1.06] | .35     |
| %RV                     | 1.01 [0.99–1.04] | .31     |
| %RV/TLC                 | 1.00 [0.98–1.02] | .77     |
| %DLCO                   | 1.00 [0.98–1.03] | .88     |
| %DLCO/VA                | 0.99 [0.97–1.02] | .63     |
| KL-6                    | 1.00 [0.99–1.01] | .94     |
| GAP score stage         | 1.07 [0.54–2.13] | .85     |
| Flat chest index        | 0.42 [0.01–50.00] | .72     |
| HOT + NPPV              | 0.25 [0.06–1.12] | .07     |

The data are presented as hazard ratio [95% confidence interval]

HR hazard ratio, CI confidence interval, SRH sleep-related hypoventilation, PPFE pleuroparenchymal fibroelastosis, BMI body mass index, PaCO2 arterial carbon dioxide partial pressure in awaking, PtCO2 transcutaneous carbon dioxide monitoring during sleep, HCO3⁻ hydrogen carbonate in awaking arterial blood gas analysis, %FEV1 %forced expiratory volume in one second, %FVC %forced vital capacity, FEV1/FVC forced expiratory volume in one second/forced vital capacity, %VC %vital capacity, %TLC %total lung capacity, %RV %residual volume, %DLCO %diffusing capacity for carbon monoxide, %DLCO/VA %diffusing capacity for carbon monoxide, KL-6 Krebs von den lungen-6, GAP gender-age-physiology, HOT + NPPV introducing home oxygen therapy (HOT) in daytime plus non-invasive positive pressure ventilation (NPPV)

Table 5 Univariate and multivariate analysis of prognostic factors of total PPFE

|                      | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | HR [95% CI] | p-value | HR [95% CI] | p-value |
| Age                  | 1.00 [0.97–1.04] | .84     | 1.11 [0.47–2.61] | .81     |
| Smoking history      | 1.11 [0.47–2.61] | .81     | 1.05 [0.10–1.09] | .52     |
| BMI                  | 0.74 [0.65–0.85] | <.01    | 0.68 [0.56–0.83] | <.01    |
| Gender (male)        | 1.02 [0.42–2.46] | .66     | 1.05 [0.10–1.09] | .52     |
| PaCO2                | 0.98 [0.95–1.00] | .08     | 0.96 [0.94–0.99] | .01     |
| HCO3⁻                | 1.23 [0.90–1.38] | <.01    | 0.96 [0.94–0.99] | <.01    |
| PtCO2, mean          | 1.04 [0.10–1.07] | .02     | 0.96 [0.94–0.99] | <.01    |
| PtCO2, max           | 1.03 [0.10–1.06] | .01     | 0.96 [0.94–0.99] | <.01    |
| %FEV1                | 0.98 [0.95–1.00] | .08     | 0.96 [0.94–0.99] | <.01    |
| %RV                  | 0.99 [0.99–1.01] | .94     | 0.96 [0.94–0.99] | <.01    |
| %RV/TLC              | 0.98 [0.96–0.99] | .04     | 0.96 [0.94–0.99] | <.01    |
| %DLCO                | 0.98 [0.96–0.99] | .04     | 0.96 [0.94–0.99] | <.01    |
| KL-6                 | 0.98 [0.96–0.99] | .04     | 0.96 [0.94–0.99] | <.01    |
| GAP score stage      | 1.5 [1.12–2.02] | <.01    | 2.44 [1.09–5.46] | .03     |
| Flat chest index     | 0.01 [0.01–1.14] | .06     | 0.02 [0.01–1.14] | .06     |
| HOT + NPPV           | 1.15 [0.39–3.43] | .08     | 1.15 [0.39–3.43] | .08     |
| SRH                  | 5.36 [1.94–14.82] | <.01    | 4.84 [1.31–17.93] | .02     |

The data are presented as hazard ratio [95% confidence interval]

HR hazard ratio, CI confidence interval, SRH sleep-related hypoventilation, PPFE pleuroparenchymal fibroelastosis, BMI body mass index, PaCO2 arterial carbon dioxide partial pressure in awaking, PtCO2 transcutaneous carbon dioxide monitoring during sleep, HCO3⁻ hydrogen carbonate in awaking arterial blood gas analysis, %FEV1 %forced expiratory volume in one second, %FVC %forced vital capacity, FEV1/FVC forced expiratory volume in one second/forced vital capacity, %VC %vital capacity, %TLC %total lung capacity, %RV %residual volume, %DLCO %diffusing capacity for carbon monoxide, %DLCO/VA %diffusing capacity for carbon monoxide, KL-6 Krebs von den lungen-6, GAP gender-age-physiology, HOT + NPPV introducing home oxygen therapy (HOT) in daytime plus non-invasive positive pressure ventilation (NPPV)
In this study, six patients had CPA when they were diagnosed as SRH. Those patients fulfilled PPFE criteria, therefore, they were included in 28 PPFE patients with SRH. Fourth, since electroencephalography was not performed concurrently with TOSCA® during sleep, sleep stages were not evaluated. The analysis of the effect of REM sleep on SRH in patients with PPFE may be important; therefore, the addition of electroencephalography is recommended in future studies.

**Conclusion**

This study indicates that SRH is a poor prognostic factor for PPFE. Progression of pulmonary fibrosis and reduction in lung volume may be associated with SRH in patients with PPFE. HOT plus NPPV may improve the prognosis of PPFE patients with SRH, although the risk of pneumothorax and oxygen-induced nocturnal hypoventilation must be accurately assessed. In addition, SRH may modify Aspergillus infection in PPFE.

**Abbreviations**

AASM: American Academy of Sleep Medicine; ABG: Arterial blood gas; ATS: American Thoracic Society; BA: Bronchial asthma; BMI: Body mass index; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; CPA: Chronic pulmonary aspergillosis; CXR: Chest X ray; DLCO: Diffusing capacity for carbon monoxide; DLCO/VA: Diffusing capacity for carbon monoxide/alveolar volume; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; GAP: Gender-age-physiology; HCO3−: Hydrogen carbonate in awakening arterial blood gas analysis; HOT: Home oxygen therapy; HR: Hazard ratio; HRCT: High-resolution computed tomography; ICSD: International Classification of Sleep Disorder; IIP: Idiopathic interstitial pneumonia; ILD: Interstitial lung disease; IPP: Idiopathic pulmonary fibrosis; NPPV: Non-invasive positive pressure ventilation; PaCO2: Arterial carbon dioxide partial pressure in awaking; NSIP: Non-specific interstitial pneumonia; PFT: Pulmonary function test; PPFE: Pleuroparenchymal fibroelastosis; PrCO2: Transcutaneous carbon dioxide monitoring during sleep; REM: Rapid eye movement; RV: Residual volume; SRH: Sleep related hypoventilation; TEC: Total lung capacity; UIP: Usual interstitial pneumonia; VC: Vital capacity.

**Acknowledgements**

Editorial support, in the form of medical writing, assembling tables, and creating high-resolution images based on authors’ detailed directions, collating author comments, copyediting, fact checking, and referencing, was provided by Editage, Cactus Communications.

**Author contributions**

YY and TS contributed to the study design and concept. YY and TS analyzed the data, and YY drafted the manuscript. HH, MN, NA, JK, and KH1 supervised data analysis and construction of the manuscript. YM, SU, SO, KH2, and TS revised the manuscript accordingly. KY, TK, MM and NH critically reviewed the manuscript. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

The study was conducted with approval from Institutional Ethics Committee in Ibaraki Higashi national Hospital (No. 2019-027). The opt-out method was used for patient consent instead of obtaining informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no conflicts of interest.

**Author details**

1Department of Respiratory Medicine, National Hospital Organization, Ibaraki Higashi National Hospital, 825 Terunuma, Tokai-Mura, Naka-Gun, Ibaraki 319-1113, Japan. 2Department of Clinical Research, National Hospital Organization, Ibaraki Higashi National Hospital, Ibaraki, Japan. 3Department of Radiology, National Hospital Organization, Ibaraki Higashi National Hospital, Ibaraki, Japan. 4Department of Radiology, National Defense Medical College, Saitama, Japan. 5Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

**Received:** 24 May 2022   **Accepted:** 17 October 2022

**Published online:** 31 October 2022

**References**

1. Bonifazi M, Montero MA, Renzoni EA. Idiopathic pleuroparenchymal fibroelastosis. Curr Pulmonol Rep. 2017;6:9–15.

2. Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, et al. Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. Ann Thorac Soc. 2019;16:1351–9.

3. Tanizawa K, Handa T, Kubo T, Chen-Yoshikawa TF, Aoyama S, Motoyama H, et al. Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study. Respir Res. 2018;19:162.

4. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.

5. Böing S, Randerath WJ. Chronic hypoventilation syndromes and sleep-related hypoventilation. J Thorac Dis. 2015;7:1273–85.

6. McNicholas WT, Hansson D, Schiza S, Grote L. Sleep in chronic respiratory disease: COPD and hypoventilation disorders. Eur Respir Rev. 2019;28:190064.

7. Budhijara R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med. 2015;11:259–70.

8. Kitajima T, Marumo S, Shima H, Shirata M, Kawashima S, Inoue D, et al. Clinical impact of episodic nocturnal hypercapnia and its treatment with noninvasive positive pressure ventilation in patients with stable advanced COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:843–53.

9. Meyers F, Jones CM, Gehrke K, Gehrke K, Jones CM, Meyers F. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. https://doi.org/10.1164/rccm.201909-1980ST

10. Ley B, Ryerson JC, Wittninghoff E, Ryu HJ, Tomassetti S, Lee SJ, et al. Multi-dimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012. https://doi.org/10.7326/0003-4819-156-10-201205150-00004.

11. Schmidt GA. Monitoring gas exchange. Respir Care. 2020;65:729–38.

12. Storre JH, Magnet FS, Dreher M, Windisch W. Transcutaneous monitoring during sleep, sleep stages were not evaluated. The analysis of effect of REM sleep on SRH in patients with PPFE may be important; therefore, the addition of electroencephalography is recommended in future studies.

13. Harada T, Yoshida Y, Kitasato Y, Tsuruta N, Wakamatsu K, Hirota T, et al. The thoracic cage becomes flattened in the progression of pleuroparenchymal fibroelastosis. Eur Respir Rev. 2014;23:263–6.

14. Oda T, Sekine A, Tabata E, Iwasawa T, Takemura T, Ogura T. Comparison of clinical characteristics and outcomes between idiopathic and secondary pleuroparenchymal fibroelastosis. J Clin Med. 2021;10:846.
15. Kinoshita Y, Ikeda T, Miyamura T, Ueda Y, Yoshida Y, Kushima H, et al. A proposed prognostic prediction score for pleuroparenchymal fibroelastosis. Respir Res. 2021;22:215.

16. Shioya M, Otsuka M, Yamada G, Umeda Y, Ikeda K, Nishikiori H, et al. Poorer prognosis of idiopathic pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis in advanced stage. Can Respir J. 2018;2018:1–7.

17. Ikeda T, Kinoshita Y, Miyamura T, Ueda Y, Yoshida Y, Kushima H, et al. Pleuroparenchymal fibroelastosis progresses with lung involvement in pleuroparenchymal fibroelastosis. Respir Investig. 2022;60:293–9.

18. Reddy TL, Tominaiga M, Hansell DM, von der Thesen J, Rassl D, Parfrey H, et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J. 2012;40:377–85.

19. Namba M, Masuda T, Takao S, Terada H, Yamaguchi K, Sakamoto S, et al. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis. Respir Investig. 2020;58:465–72.

20. Enomoto Y, Nakamura Y, Satake Y, Sumikawa H, Joohko T, Colby TV, et al. Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: a retrospective multicenter study. Respir Med. 2017;133:1–5.

21. Global Strategy for Diagnosis, management, and prevention of COPD—2016 [Internet]. The global initiative for chronic obstructive lung disease (GOLD). https://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed 26 Aug 2022.

22. Global Initiative for Asthma [Internet]. Glob. Initiat. Asthma—GINA. https://ginasthma.org/. Accessed 26 Aug 2022.

23. Denning DW, Cadranel J, Beigelman-Aubry C, Ador F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45–68.

24. American Thoracic Society/European Respiratory Society International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. https://doi.org/10.1164/ajrccm.165.2.ats01

25. Watanabe S, Waseda Y, Takato H, Matsunuma R, Joohkoh T, Egashira R, et al. Pleuroparenchymal fibroelastosis: Distinct pulmonary physiological features in nine patients. Respir Investig. 2015;53:149–55.

26. Ishii H, Kinoshita Y, Kushima H, Nagata N, Watanabe K. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis. Chron Respir Dis. 2019;16:147997311986794.

27. Watanabe K. Pleuroparenchymal fibroelastosis: its clinical characteristics. Curr Respir Med Rev. 2013;9:229–37.

28. Jones DJM, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med. 2012. https://doi.org/10.1164/ajrccm.152.2.7633704.

29. Fukushima K, Marut K, Kyofufu C, Sugimoto M [Evaluation of the incidence of pneumothorax and background of patients with pneumothorax during noninvasive positive pressure ventilation]. Nihon Kokyuki Gakkai Zasshi. 2008;46:870–4.

30. Vianello A, Arcauro G, Gallian F, Ori C, Bivacqua M. Pneumothorax associated with long-term non-invasive positive pressure ventilation in Duchenne muscular dystrophy. Neuromuscul Disord. 2004;14:353–5.

31. Kelly A-M, Klim S. Agreement between arterial and transcutaneous PCO2 in patients undergoing non-invasive ventilation. Respir Med. 2011;105:226–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.